Document Detail

An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial.
MedLine Citation:
PMID:  20884379     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Only a minority of patients receiving implantable cardioverter-defibrillators (ICDs) for the primary prevention of sudden death receive appropriate shocks, yet almost as many are subjected to inappropriate shocks and device complications. Identifying and quantifying myocardial scar, which forms the substrate for ventricular tachyarrhythmias, may improve risk stratification.
OBJECTIVE: This study sought to determine whether the absence of myocardial scar detected by novel 12-lead electrocardiographic (ECG) Selvester QRS scoring criteria identifies patients with low risk for appropriate ICD shocks.
METHODS: We applied QRS scoring to 797 patients from the ICD arm of the Sudden Cardiac Death in Heart Failure Trial. Patients were followed up for a median of 45.5 months for ventricular tachycardia/fibrillation treated by the ICD or sudden tachyarrhythmic death (combined group referred to as VT/VF).
RESULTS: Increasing QRS score scar size predicted higher rates of VT/VF. Patients with no scar (QRS score = 0) represented a particularly low-risk cohort with 48% fewer VT/VF events than the rest of the population (absolute difference 11%; hazard ratio 0.52, 95% confidence interval 0.31 to 0.88). QRS score scar absence versus presence remained a significant prognostic factor after controlling for 10 clinically relevant variables. Combining QRS score (scar absence versus presence) with ejection fraction (≥ 25% versus < 25%) distinguished low-, middle-, and high-risk subgroups with 73% fewer VT/VF events in the low-risk versus high-risk group (absolute difference 22%; hazard ratio = 0.27, 95% confidence interval 0.12 to 0.62).
CONCLUSION: Patients with no scar by QRS scoring have significantly fewer VT/VF events. This inexpensive 12-lead ECG tool provides unique, incremental prognostic information and should be considered in risk-stratifying algorithms for selecting patients for ICDs.
David G Strauss; Jeanne E Poole; Galen S Wagner; Ronald H Selvester; Julie M Miller; Jill Anderson; George Johnson; Steven E McNulty; Daniel B Mark; Kerry L Lee; Gust H Bardy; Katherine C Wu
Related Documents :
15546309 - Feasibility of catheter cryoablation in normal ventricular myocardium and healed myocar...
18002839 - Ventricular arrhythmias assessment.
9201629 - Epinephrine facilitates cardiac fibrillation by shortening action potential refractorin...
6207719 - Vulnerability to ventricular fibrillation in patients with clinically manifest ventricu...
1451259 - Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart.
11502049 - Left ventricular epicardial outflow tract tachycardia: a new distinct subgroup of outfl...
15620989 - Hydrodissection in redo sternotomies.
16044169 - Memokath stents for the treatment of detrusor sphincter dyssynergia (dsd) in men with s...
17470329 - Race-related differences in heart failure therapies: simply black and white or shades o...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-09-25
Journal Detail:
Title:  Heart rhythm : the official journal of the Heart Rhythm Society     Volume:  8     ISSN:  1556-3871     ISO Abbreviation:  Heart Rhythm     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-27     Completed Date:  2011-05-24     Revised Date:  2014-09-24    
Medline Journal Info:
Nlm Unique ID:  101200317     Medline TA:  Heart Rhythm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  38-45     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cicatrix / pathology
Death, Sudden, Cardiac / prevention & control*
Defibrillators, Implantable* / adverse effects
Equipment Failure Analysis
Heart Conduction System / physiopathology
Heart Failure / therapy*
Middle Aged
Myocardium / pathology*
Risk Assessment
Grant Support
U01 HL055297-03/HL/NHLBI NIH HHS; U01 HL055297-04/HL/NHLBI NIH HHS; U01 HL055297-05/HL/NHLBI NIH HHS; U01 HL055297-06/HL/NHLBI NIH HHS; U01 HL055297-07/HL/NHLBI NIH HHS; U01 HL055496/HL/NHLBI NIH HHS; U01 HL055496-03/HL/NHLBI NIH HHS; U01 HL055496-04/HL/NHLBI NIH HHS; U01 HL055496-05/HL/NHLBI NIH HHS; U01 HL055496-05S1/HL/NHLBI NIH HHS; U01 HL055496-06/HL/NHLBI NIH HHS; U01 HL055496-07/HL/NHLBI NIH HHS; U01 HL055766/HL/NHLBI NIH HHS; U01 HL055766-03/HL/NHLBI NIH HHS; U01 HL055766-04/HL/NHLBI NIH HHS; U01 HL055766-05/HL/NHLBI NIH HHS; U01 HL055766-06/HL/NHLBI NIH HHS; U01 HL055766-07/HL/NHLBI NIH HHS; U01 HL55297/HL/NHLBI NIH HHS; U01 HL55496/HL/NHLBI NIH HHS; U01 HL55766/HL/NHLBI NIH HHS
Comment In:
Heart Rhythm. 2011 Jan;8(1):46-7   [PMID:  20951233 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A supraventricular tachycardia with two atrial activation sequences: What is the mechanism?
Next Document:  Complete antral encirclement is not required for pulmonary vein isolation.